Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dexamethasone erythrocyte encapsulated - Quince Therapeutics

Next Previous
Search
Drug Profile

Dexamethasone erythrocyte encapsulated - Quince Therapeutics

Alternative Names: Dexa 21-P – Quince Therapeutics; Dexamethasone sodium phosphate; Ery-Dex; EryDex

Latest Information Update: 10 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator EryDel
  • Developer Quince Therapeutics
  • Class Anti-inflammatories; Antiallergics; Antiemetics; Antihyperglycaemics; Antineoplastics; Antirheumatics; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Ketones; Non-opioid analgesics; Phosphates; Pregnadienetriols; Small molecules; Sodium compounds; Vestibular disorder therapies
  • Mechanism of Action Glucocorticoid receptor agonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis; Ataxia telangiectasia
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Ataxia telangiectasia
  • No development reported Duchenne muscular dystrophy
  • Discontinued Chronic obstructive pulmonary disease; Crohn's disease; Cystic fibrosis; Ulcerative colitis

Most Recent Events

  • 04 Feb 2025 Quince receives patent allowance for Dexamethasone erythrocyte encapsulated in the US
  • 11 Dec 2024 Quince Therapeutics initiates a phase III OLE_NEAT trial in Ataxia telangiectasia (In adolescents, In adults, In children, In the elderly) in USA (NCT06664853)
  • 28 Nov 2024 No recent reports of development identified for phase-I development in Duchenne muscular dystrophy in United Kingdom (IV, Infusion)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top